Do BRAF inhibitors select for populations with different disease progression kinetics?

Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experience a very rapid progression of disease. Such selectivity for more rapid disease progressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo Antonio, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599508/
https://www.ncbi.nlm.nih.gov/pubmed/23497384
http://dx.doi.org/10.1186/1479-5876-11-61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599508/
https://www.ncbi.nlm.nih.gov/pubmed/23497384
http://dx.doi.org/10.1186/1479-5876-11-61

Ejemplares similares